• Modern possibilities of the metabolic correction of the protein-energy malnutrition against the background of the CNS perinatal injuries among first year children
To content

Modern possibilities of the metabolic correction of the protein-energy malnutrition against the background of the CNS perinatal injuries among first year children

SOVREMENNAYA PEDIATRIYA.2014.4(60):63-67;doi 10.15574/SP.2014.60.63

Modern possibilities of the metabolic correction of the protein-energy malnutrition against the background of the CNS perinatal injuries among first year children

Tokarchuk N. I., Chygyr I. V. 
National Medical University named afterM.I Pirogov, Vinnitsya, Ukraine

Purpose: the clinical effectiveness evaluation of the metabolic correction of the protein-energy malnutrition (PEM) among first year children against the background of the CNS perinatal injuries.

Patients and methods: there were observed 78 children in age from 1 to 12 months. The study was based on the children's clinical observation evaluating their physical development. For the lipid disorders diagnosis it was determined the cholesterol level, triglycerides and lipoproteins blood serum with an immune-fermental method. 39 children of the 1 grope got a PEM complex therapy in a combination with a levocarnitine drug (Agvantar), 39 children got only the traditional therapy (comparison group).The therapy complex included the diet, vitamin, enzyme therapies and pro- and prebiotics.

Results: using a levocarnitine drug it was noted a significant cholesterol levels increasing, triglycerides and LDL (р<0.05).The second group of children with the traditional therapy had no index changes (р>0.05).There were no side effects of the drug.

Conclusion: it was proved the clinical effectiveness of the levocarnitine drug in a complex PEM therapy against the background of the CNS perinatal injuries among first year children, the tolerability and no side effects.

Key words: first year children, of the protein-energy malnutrition (PEM), Agvantar.

REFERENCES 
1. Ключников СО. 2007. Перспективы применения L-карнитина в педиатрии. Сonsilium medicum. Педиатрия. 2: 143—146.

2. Санакоева ЛП, Корюкина ИП. 2006. Клинические особенности гипотрофии у детей раннего возраста в Пермском регионе. Педиатрия. 2: 92—95.

3. Скворцова ВА, Нетребенко ОК, Боровик ТЭ. Нарушения питания у детей раннего возраста. Педиатрия. Симпозиум 01/11.

4. Геппе НА и др. 2010. Эффективность L-карнитина в реабилитации детей после перенесенных острых респираторных заболеваний. Вопр практич педиатрии. 5;2: 50—56.

5. Scaglia F. 2014. Carnitine Deficiency Clinical Presentation. http://emedicine.medscape.com/article/942233_overview.

6. Azevedo VM, Albanesi Filho FM, Santos MA et al. 2005. The role of L-carnitine in nutritional status and echocardiographic parameters in idiopathic dilated cardiomyopathy in children. J Pediatr (Rio J). 81(5): 368—72. http://dx.doi.org/10.1590/S0021-75572005000600005http://dx.doi.org/10.2223/JPED.1387; PMid:16247537

7. Jahoor F, Badaloo A, Reid M et al. 2008. Protein metabolism in severe childhood malnutrition. Ann Trop Paediatr. 28(2): 87—101. http://dx.doi.org/10.1179/146532808X302107; PMid:18510818

8. Flanagan JL, Simmons PA, Vehige J et al. 2010. Role of carnitine in disease. Nutrition & Metabolism. 10.1186/1743—7075—7—30. http://dx.doi.org/10.1186/1743-7075-7-30